Canadian and US developers to trial psychedelic medicines in UK
European Pharmaceutical Review
DECEMBER 13, 2022
North American psychedelic drug developers Mindset, PharmAla, Mydecine and Psyence have signed with clinical research organisation (CRO) Clerkenwell Health to trial therapies for mental health conditions, in London, UK, to benefit from the country’s swift drug regulatory process.
Let's personalize your content